SCHEMBL23606783

SCHEMBL23606783

C=CC(=O)Nc1cc(N2CCN(CC)CC2)ccc1Nc1ncc(C#N)c(Nc2cc(C#N)ccc2OC(C)C)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK3 P52333 2/20 0.49
▸ EGFR P00533 1/20 0.48
▸ MAPK3 P27361 11/20 0.47
▸ FGFR1 P11362 5/20 0.46
▸ FGFR4 P22455 5/20 0.46
▸ FGFR2 P21802 1/20 0.46
▸ FGFR3 P22607 1/20 0.46
▸ AURKA O14965 1/20 0.44
▸ DAPK3 O43293 1/20 0.44
▸ JAK2 O60674 1/20 0.44
▸ PRKD3 O94806 1/20 0.44
▸ MAP4K4 O95819 1/20 0.44
▸ PAK4 O96013 1/20 0.44
▸ LCK P06239 1/20 0.44
▸ FYN P06241 1/20 0.44
▸ CSF1R P07333 1/20 0.44
▸ RET P07949 1/20 0.44
▸ IGF1R P08069 1/20 0.44
▸ PIM1 P11309 1/20 0.44
▸ PDGFRA P16234 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30044388 1.00 JAK3 (0.49) JAK3EGFRMAPK3FGFR1FGFR4
SCHEMBL23606861 0.95 JAK3 (0.52) JAK3EGFRMAPK3FGFR1FGFR4
SCHEMBL30044337 0.95 JAK3 (0.52) JAK3EGFRMAPK3FGFR1FGFR4
SCHEMBL30044249 0.93 MAPK3 (0.52) JAK3EGFRMAPK3FGFR1FGFR4
SCHEMBL23606369 0.93 MAPK3 (0.50) JAK3EGFRMAPK3FGFR1FGFR4
SCHEMBL30045153 0.93 MAPK3 (0.50) JAK3EGFRMAPK3FGFR1FGFR4
SCHEMBL23606781 0.93 MAPK3 (0.52) JAK3EGFRMAPK3FGFR1FGFR4
SCHEMBL25140070 0.92 JAK3 (0.54) JAK3EGFRMAPK3FGFR1FGFR4
SCHEMBL23606836 0.91 EGFR (0.52) JAK3EGFRMAPK3FGFR1FGFR4
SCHEMBL30044988 0.91 EGFR (0.52) JAK3EGFRMAPK3FGFR1FGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230125046-A1 CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2023-04-20 — — US disclosed
WO-2021129561-A1 CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 北京赛特明强医药科技有限公司 2021-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230125046-A1 CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF FGFR4, FGFR1, WEE1 JAK3 372/4885EGFR 561/4885MAPK3 809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback